Translational Development Acquisition Corp.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $208.5M
- Price
- $10.80
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.18%
- Volume
- 1.8K
About
Translational Development Acquisition Corp., founded in 2022 and headquartered in New York, New York, currently conducts no significant business operations. Its primary goal is to complete a business combination, such as a merger, amalgamation, share exchange, asset acquisition, share purchase, or reorganization, with one or more companies.
Quick stats
Shares outstanding19.3M
Computed float19.3M
Float / shares100.0%
Cash runway (months)-4.2
Key info
SectorFinancial Services
IndustryShell Companies
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001926599
AI Summary
AI-generated1/11
standardbullishpartnership
Mercedes-Benz and ProLogium have entered into a joint testing agreement, including a preliminary technology evaluation of ProLogium’s latest Gen4 Superfluidized All Inorganic Solid State Battery Cell Technology
Mercedes-Benz and ProLogium signed a joint testing agreement giving the automaker priority access to ProLogium's Gen4 solid-state battery cells, extending a partnership dating to 2016 in which Mercedes-Benz invested in and holds a board seat at ProLogium.
ProLogium is the target of a definitive business combination with Translational Development Acquisition Corp. (Nasdaq: TDAC), with a Nasdaq listing expected in 4Q2026 under ticker PRLG, pending approvals.
ProLogium's Dunkirk, France gigafactory is designed for up to 44 GWh of capacity (4 GWh in phase one by 2030); the Taoke, Taiwan plant has completed GWh-scale manufacturing validation.
The Mercedes-Benz testing deal is a technology-validation win for the SPAC's target, though it stops short of a commercial supply agreement.
Red flags
- Testing agreement is an evaluation, not a commercial supply contract
- TDAC-ProLogium business combination still subject to regulatory approvals and listing conditions